Related references
Note: Only part of the references are listed.Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin
X. A. Alvarez et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Spotlight on Cerebrolysin in Dementia
Greg L. Plosker et al.
CNS DRUGS (2010)
Progressive accumulation of amyloid-β oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins
Emiley Pham et al.
FEBS JOURNAL (2010)
Cerebrolysin Enhances Neurogenesis in the Ischemic Brain and Improves Functional Outcome After Stroke
Chunling Zhang et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2010)
Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin
Kiren Ubhi et al.
ACTA NEUROPATHOLOGICA (2009)
Cerebrolysin A Review of its Use in Dementia
Greg L. Plosker et al.
DRUGS & AGING (2009)
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease
Alan H. Nagahara et al.
NATURE MEDICINE (2009)
Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice
Brian Spencer et al.
BMC NEUROSCIENCE (2008)
Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury
X. Anton Alvarez et al.
JOURNAL OF NEURAL TRANSMISSION (2008)
A pilot study to evaluate the effects of cerebrolysin on cognition and qEEG in vascular dementia: Cognitive improvement correlates with qEEG acceleration
Dafin F. Muresanu et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2008)
Transgenic animal models of neurodegenerative diseases and their application to treatment development
Edward Rockenstein et al.
ADVANCED DRUG DELIVERY REVIEWS (2007)
Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis
Honghui Chen et al.
NEUROBIOLOGY OF AGING (2007)
Effects of Cerebrolysin™ on neurogenesis in an APP transgenic model of Alzheimer's disease
Edward Rockenstein et al.
ACTA NEUROPATHOLOGICA (2007)
Neuroprotective effects of regulators of the glycogen synthase kinase-3β signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation
Edward Rockenstein et al.
JOURNAL OF NEUROSCIENCE (2007)
Nerve growth factor gene therapy in Alzheimer disease
Mark H. Tuszynski
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2007)
Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users
G. Chana et al.
NEUROLOGY (2006)
Cerebrolysin decreases amyloid-β production by regulating amyloid protein precursor maturation in a Transgenic model of Alzheimer's disease
Edward Rockenstein et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2006)
A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease
XA Alvarez et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
High β-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-β levels -: Implications for the treatment of Alzheimer disease
E Rockenstein et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
MH Tuszynski et al.
NATURE MEDICINE (2005)
Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound Cerebrolysin™
E Rockenstein et al.
JOURNAL OF NEURAL TRANSMISSION (2005)
Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: Evidence for decreased neuronal somal size and increased neuronal density
G Chana et al.
BIOLOGICAL PSYCHIATRY (2003)
The neuroprotective effects of Cerebrolysin (TM) in a transgenic model of Alzheimer's disease are associated with improved behavioral performance
E Rockenstein et al.
JOURNAL OF NEURAL TRANSMISSION (2003)
Early formation of mature amyloid-β protein deposits in a mutant APP transgenic model depends on levels of Aβ1-42
E Rockenstein et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2001)
Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease
E Masliah et al.
NEUROLOGY (2001)
Apoptosis modulators in the therapy of neurodegenerative diseases
HP Deigner et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2000)
Inhibitory effect of a brain derived peptide preparation on the Ca++-dependent protease, calpain
R Wronski et al.
JOURNAL OF NEURAL TRANSMISSION (2000)
Neurotrophic effects of FPF-1070 (Cerebrolysin (R)) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks
T Satou et al.
JOURNAL OF NEURAL TRANSMISSION (2000)
Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy
E Ruther et al.
JOURNAL OF NEURAL TRANSMISSION (2000)